Li-Fraumeni syndrome and the role of the p53 tumor suppressor gene in cancer susceptibility.
Mutation of the tumor suppressor gene p53 is a molecular genetic event frequently observed in human cancer, and inactivating missense mutations usually are accompanied by the resultant overexpression of mutant p53 protein. In gynecologic cancers, p53 is also often altered; the frequency varies depending on types of cancers and where they develop. Further, human papillomavirus oncoproteins that inactivate p53 and Rb proteins play important roles in the development of several gynecologic cancers. Individuals who are heterozygous for germline mutations of the p53 gene are strongly predisposed to a variety of cancers. The identification of these individuals may have profound value in the future when therapies or chemopreventive agents specific for the p53 alteration are available. The role of p53 tumor suppressor gene in gynecologic cancers and heritable cancer susceptibility syndromes including Li-Fraumeni and Lynch II syndromes is an active and important area of study.
Akashi
M
M
Division of Radiation Health, National Institute of Radiological Sciences, Chiba, Japan.
Koeffler
H P
HP
D005260:Female; D005786:Gene Expression Regulation; D016158:Genes, p53 / Q000235:genetics; D020022:Genetic Predisposition to Disease; D015316:Genetic Therapy; D005833:Genital Neoplasms, Female / Q000235:genetics; D018095:Germ-Line Mutation; D006801:Humans; D016864:Li-Fraumeni Syndrome / Q000235:genetics*; D009386:Neoplastic Syndromes, Hereditary / Q000235:genetics* / Q000628:therapy; D014158:Transcription, Genetic